Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Takeda Pharmaceutical Ltd ADR (NY: TAK ) 14.32 UNCHANGED Streaming Delayed Price Updated: 7:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 14.32 Bid (Size) 14.05 (4) Ask (Size) 14.80 (5) Prev. Close 14.32 Today's Range 14.32 - 14.32 52wk Range 12.57 - 15.47 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda September 24, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Performance YTD -0.14% -0.14% 1 Month -4.02% -4.02% 3 Month +9.23% +9.23% 6 Month +5.84% +5.84% 1 Year -4.21% -4.21% More News Read More Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut September 20, 2024 Via MarketBeat Topics Economy Exposures Interest Rates Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024 September 19, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries September 18, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines September 10, 2024 Via Benzinga Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst September 09, 2024 Via Benzinga Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production September 06, 2024 Via Benzinga Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues August 12, 2024 Via Benzinga Exposures Product Safety New Study Reveals How Classical Music Could Revolutionize Depression Care August 12, 2024 Via PressReach Exposures Product Safety Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? August 07, 2024 Via Benzinga Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) August 07, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024 July 31, 2024 Via InvestorPlace Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline July 31, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire 3 Biotech Stocks to Buy on the Dip: July 2024 July 29, 2024 Via InvestorPlace Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation July 24, 2024 Via Benzinga Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst July 09, 2024 Via Benzinga Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma July 06, 2024 Via Talk Markets Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report July 02, 2024 Via Benzinga Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 June 28, 2024 Via Investor's Business Daily Topics Stocks Exposures US Equities Takeda Announces New Assignments of Directors June 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies June 24, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia June 22, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer June 21, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda June 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.